Dientamoebiasis medical therapy

Dientamoebiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Dientamoebiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Case Studies
Case #1
Dientamoebiasis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dientamoebiasis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dientamoebiasis medical therapy
CDC on Dientamoebiasis medical therapy
Dientamoebiasis medical therapy in the news
Blogs on Dientamoebiasis medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Dientamoebiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Kalsang Dolma, M.B.B.S.[2]

Medical Therapy

Shown below is a table summarizing the empiric treatment for dientamoebiasis.

Pathogens	Preferred Treatment	Duration of Treatment
Dientamoeba fragilis	Iodoquinol 650 mg orally 3 times daily OR Paromomycin 25–35 mg per kg per day orally, in 3 divided doses OR Metronidazole (2) 500–750 mg orally 3 times daily	Iodoquinol for 20 days OR Paromomycin for 7 days OR Metronidazole for 10 days

(1). Not FDA-approved for this indication.

(2). Metronidazole is a nitroimidazole drug. The nitroimidazole drugs secnidazole and ornidazole have been used to treat D. fragilis infection but are unavailable in the United States.

References

Template:WikiDoc Sources